← All trials
NCT07296614
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 25, 2025
- Primary completion
- Jul 30, 2028
- Completion date
- Jul 30, 2028
- First posted
- Dec 22, 2025
- Last posted
- Dec 22, 2025
- Enrollment
- 320
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Capital Medical UniversityCollaborator
- Peking UniversityCollaborator
- Dongfang Hospital Beijing University of Chinese MedicineCollaborator
- Heilongjiang University of Traditional Chinese MedicineCollaborator
- Guangdong Provincial Hospital of Traditional Chinese MedicineCollaborator
- Hunan Provincial Maternal and Child Health Care HospitalCollaborator
- Hunan University of Traditional Chinese MedicineCollaborator
- Shandong UniversityCollaborator
- Nanjing UniversityCollaborator
- Tianjin University of Traditional Chinese MedicineCollaborator
- Zhengzhou UniversityCollaborator
- Peking UniversityCollaborator
- Xiamen UniversityCollaborator
- China Academy of Chinese Medical SciencesCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.